Prognostic value of FOXP3+ regulatory T cells in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis

被引:5
|
作者
Bai, Yuping [1 ]
He, Tingting [1 ]
Zhang, Liyan [2 ]
Liu, Qianqian [1 ]
Yang, Jing [1 ]
Zhao, Ziru [1 ]
Yang, Kehu [3 ]
Zhang, Min [4 ]
机构
[1] Gansu Univ Chinese Med, Sch Basic Med, Lanzhou, Peoples R China
[2] Hebei Cangzhou Hosp Integrated Tradit Chinese & W, Dept Pathol, Cangzhou, Peoples R China
[3] Lanzhou Univ, Evidence Based Med Ctr, Sch Basic Med Sci, Lanzhou, Peoples R China
[4] Gansu Prov Hosp, Dept Pathol, Lanzhou, Peoples R China
来源
BMJ OPEN | 2022年 / 12卷 / 09期
基金
中国国家自然科学基金;
关键词
lymphoma; immunology; haematology; PREDICTS POOR-PROGNOSIS; TUMOR MICROENVIRONMENT; EXPRESSION; RITUXIMAB; CYCLOPHOSPHAMIDE; VINCRISTINE; IMPACT;
D O I
10.1136/bmjopen-2021-060659
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives We aimed to comprehensively evaluate the relationship between forkhead box P3 (FOXP3(+)) regulatory T cell (Treg) expression and diffuse large B-cell lymphoma (DLBCL) prognosis and to explore the sources of heterogeneity of the results. Design Systematic review and meta-analysis. Data sources We searched the Cochrane Library, PubMed, Embase and Web of Science databases up to 5 December 2021. Eligibility criteria We included studies that analysed the prognostic significance of FOXP3(+) Tregs in DLBCL. We included studies reported in Chinese or English that reported HRs and related 95% CIs for prognosis. Data extraction and synthesis We extracted data from eligible studies. HRs and 95% CIs were used to assess the prognostic value. Results Fourteen eligible studies were identified. FOXP3(+) Treg expression was not associated with overall survival (OS) (HR=0.72, 95% CI 0.45 to 1.16) or progression-free survival (HR=0.86, 95% CI 0.54 to 1.38). The three approaches used to measure FOXP3(+) Treg expression (p(interaction)<0.001) may be the source of the heterogeneity of the results. Subgroup analysis found that a higher expression of FOXP3(+) Tregs was associated with better OS in all populations and in Asians when FOXP3(+) Treg expression was measured by the number of positive cells (HR=0.36 (95% CI 0.22 to 0.58) in the former, HR=0.33 (95% CI 0.20 to 0.55) in the latter) or the percentage of positive cells (HR=0.49 (95% CI 0.27 to 0.89) in the former, HR=0.38 (95% CI 0.21 to 0.70) in the latter). However, when measured by the score, inverse results were found (HR=1.56, 95% CI 1.01 to 2.42). Conclusions Approaches to measuring FOXP3(+) Treg expression might be the major source of heterogeneity in studies of the prognostic significance of FOXP3(+) Tregs in DLBCL. FOXP3(+) Treg expression might be used to predict the prognosis of patients with DLBCL when FOXP3(+) Treg expression is calculated by the number or the percentage of positive cells, especially in Asian populations.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Clinicopathological analysis of oral diffuse large B-cell lymphoma, NOS: A systematic review
    Rodrigues-Fernandes, Carla Isabelly
    de Souza, Lucas Lacerda
    dos Santos-Costa, Sara Ferreira
    Rebelo Pontes, Helder Antonio
    de Almeida, Oslei Paes
    Vargas, Pablo Agustin
    Henao, Javier Rendon
    Rahimi, Siavash
    Brennan, Peter A.
    Fonseca, Felipe Paiva
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2019, 48 (03) : 185 - 191
  • [42] The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis
    Lin, Zhijuan
    Chen, Xing
    Li, Zhifeng
    Zhou, Yong
    Fang, Zhihong
    Luo, Yiming
    Zhao, Jintao
    Xu, Bing
    ANNALS OF HEMATOLOGY, 2018, 97 (11) : 2137 - 2144
  • [43] The prognostic roles of hepatitis B virus antibody in diffuse large B-cell lymphoma patients
    Hu, Shunfeng
    Chen, Na
    Lu, Kang
    Zhen, Changqing
    Sui, Xiaohui
    Fang, Xiaosheng
    Li, Ying
    Luo, Yingshu
    Zhou, Xiangxiang
    Wang, Xin
    LEUKEMIA & LYMPHOMA, 2021, 62 (06) : 1335 - 1343
  • [44] Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement
    Lehners, Nicola
    Kraemer, Isabelle
    Saadati, Maral
    Benner, Axel
    Ho, Anthony D.
    Witzens-Harig, Mathias
    BMC CANCER, 2017, 17
  • [45] Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis
    Zhang, Jing
    Chen, Bobin
    Xu, Xiaoping
    LEUKEMIA & LYMPHOMA, 2014, 55 (03) : 509 - 514
  • [46] Efficacy and safety of lenalidomide in diffuse large B-cell lymphoma: a meta-analysis of randomized controlled trials
    Liu, Jia
    Mi, Ruihua
    Chen, Lin
    Guo, Xiaoli
    Liang, Taotao
    Yin, Qingsong
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (04) : 1161 - 1169
  • [47] Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era
    Huang, Yu-Chung
    Liu, Chun-Yu
    Lu, Hsueh-Ju
    Liu, Han-Tsung
    Hung, Man-Hsin
    Hong, Ying-Chung
    Hsiao, Liang-Tsai
    Gau, Jyh-Pyng
    Liu, Jin-Hwang
    Hsu, Hui-Chi
    Chiou, Tzeon-Jye
    Chen, Po-Min
    Tzeng, Cheng-Hwai
    Yu, Yuan-Bin
    ANNALS OF HEMATOLOGY, 2013, 92 (11) : 1513 - 1520
  • [48] The significance of chemokines in diffuse large B-cell lymphoma: a systematic review and future insights
    Huang, Qian
    Liu, Feifei
    Shen, Jianzhen
    FUTURE ONCOLOGY, 2019, 15 (12) : 1385 - 1395
  • [49] Prognostic value of regulator T cells in patients with pancreatic cancer: a systematic review and meta-analysis
    Su, K-F.
    Peng, Y.
    Yu, H-C.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (08) : 2906 - 2917
  • [50] Prognostic Factors in Elderly Patients with Diffuse Large B-Cell Lymphoma and Their Treatment Results
    Adiyaman, Suleyman Cem
    Alacacioglu, Inci
    Danyeli, Ayca Ersen
    Turkyilmaz, Dogus
    Sevindik, Omur Gokmen
    Demirkan, Fatih
    Piskin, Ozden
    Ozcan, Mehmet Ali
    Undar, Bulent
    Ozkal, Sermin
    Ozsan, Guner Hayri
    TURKISH JOURNAL OF HEMATOLOGY, 2019, 36 (02) : 81 - 87